Member Info for emptyend

No. Nothing wrong with 1.2bn shares.

I look forward a few months to when they are priced at £1 each…..

Re this new Modi-1/cohort, mentioned by Burble in the AGM thread, I note that this is acually the most common form of liver cancer (according to CRUK) and has a five year survival rate of 17% (11% with secondaries).

I wonder what evidence led them to open that cohort….

Since the placing remains conditional on the listing approval, you can’t draw any conclusions about the participation of Vulpes/Redmile re their OO takeup.

Currently in transit in Singapore for a day…..there is rising concern here about the spread of the latest Covid variant:

https://www.business-standard.com/world-news/masks-return-as-singapore-sees-covid-19-uptick-rise-in-hospitalisations-123121800708_1.html

….and the Singapore government has gone back to recommending masks in public. It is also returning to publishing, from (later) today a daily update on Covid infections etc, on the Health Ministry website. The latest weekly numbers (to Dec 9th, I believe) are here…..note the very sharp rises and consider that we are now ten days further on:

https://www.moh.gov.sg/covid-19/statistics

If only someone had a broad-based vaccine ready to go…..

Drivel from Mayo…..🙄

Nor sure why people are obsessing about getting or not getting the OO details yet.

Last time around some brokers were quicker than others….

Interesting that the implication of the placing having been “led by” new specialist investors is that the company were approached with an inquiry about how to get an initial stake.

How big and who?

Was it worth giving them a 10% discount, given that the placing was “significantly oversubscribed”? We don’t know yet……but I certainly hope so!

A “derisory” share price is not usually a good point at which to dilute existing holders…..

At some point in the coming weeks and months, the adults will arrive and reprice the shares to a whole new range. Institutions rarely muck around. Neither do big pharma companies.

…..ditto Thomas Moore……

Chester,

My personal expectation would be for an RNS’d update on the morning of the AGM.

Sometimes, however, that is exactly what happens!

And, I can tell you from firsthand experience in a listed company, “completely tight ships” are the norm, not an exception! It is a common delusion that things “must leak” - they usually don’t. Not a whisper.

…..nor far from the truth there, IMO.

Some questions simply cannot be answered legally…..

Don’t bother yourself with this. The exercise pattern of options depends entirely on the individual’s tax position. It is irrelevant to the prospects. Goodfellow’s options were not extended (he is no longer an employee and is free to exercise, whereas LD was unable to exercise due to inside info and her options were extended).

Don’t bother yourself with this. The exercise pattern of options depends entirely on the individual’s tax position. It is irrelevant to the prospects.

In my opinion, the auditor delay screwed up the IR plan. I would assume that the posters and conferences were prioritised over investors, because investors will get a proper shot at the upcoming AGM. Unfortunately I will be in Sydney that day - but I trust there will be some detailed reports.

Http://digitaleditions.telegraph.co.uk/data/1522/reader/reader.html?social#!preferred/0/package/1522/pub/1522/page/5/article/NaN

LIFE-SAVING drug trials will get the green light more quickly under plans to take advantage of Brexit to reduce red tape.

Steve Barclay, the Health Secretary, today announces a new fast-track process, which will halve the time it takes for some research to get under way.

Regulators have cleared a backlog of more than 2,000 applications, which built up after a surge of interest in research in the wake of the pandemic.

Writing jointly with June Raine, head of the Medicines and Healthcare products Regulatory Agency (MHRA), Mr Barclay pledged to streamline research processes further as part of the biggest reform of clinical trials for more than 20 years.

The changes have come about because regulators have more freedom to design their own processes following Brexit, including identifying trials that can be authorised more quickly.

Although applications should be assessed within 30 days, the average wait hit four months earlier this year, following a surge of applications. On an average year, the MHRA normally approves around 750 new trials per year.

Since July, the watchdog has approved 2,200 trials, wiping out a backlog of almost 1,000 which had stacked up. Today, Mr Barclay and Ms Raine set out plans which will mean that approval time for low-risk trials will be reduced to 14 days.…….

No need for an update. This is a networking opportunity with a different audience. Would be nice to pick up 3-4 potential partners from the various different events.....

Interesting news and intriguingly vague title.

My guess is it has come out of the Modi-1 trial research, where I think they’ve gone into “silent mode” after the early approval of cohort expansions, back in late July. I think they are sitting on something materially-encouraging.

I suspect the industry won’t make the same mistake as stock market traders. Operational progress is what matters - the gamble on price is about when the market will recognise that. My feeling is, in general, it won’t have a clue until a deal gets done on terms that make clear how wrong the ‘derisory’ market valuation has been….

Does anyone know when Cooley became their solicitors? I wonder if this was a recent change as with the specialist PR company?

It seems to me that the advisers’ roster is now perfectly equipped for deals ahead…